ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Human B7-H3 (CD276) can be quantified in various samples, including plasma, serum, supernatant.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated....ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Human B7-H3 (CD276) can be quantified in various samples, including plasma, serum, supernatant.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated....ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Human B7-H3 (CD276) can be quantified in various samples, including plasma, serum, supernatant.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated. Uncoated ELISA kits include all the necessary reagents to coat your own plates and run your assay with maximum flexibility. Coated ELISA kits...
ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Human B7-H3 (CD276) can be quantified in various samples, including plasma, serum, supernatant.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated. Uncoated ELISA kits include all the necessary reagents to coat your own plates and run your assay with maximum flexibility. Coated ELISA kits are ready-to-use and quality tested for sensitivity, specificity, precision and lot-to-lot consistency.
靶标信息
CD276 is a member of the B7 family of co-stimulatory molecules also known as B7-H3. CD276 is a type I transmembrane protein that induces the proliferation of CD4+ and CD8+ T cells, enhances the generation of cytotoxic T cells and selectively stimulates the production of interferon gamma. Expression of CD276 can be induced on dendritic cells and monocytes by inflammatory cytokines, and is also widely expressed in peripheral tissues including the heart, kidney, testis and colon. In humans, CD276 exists as two isoforms which result from gene duplication and differential splicing. CD276 is reported to have therapeutic potential for the regulation of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy.